Inhaled Nitric Oxide Treatment for Stabilization and Emergency Medical Transport of Critically Ill Newborns and Infants

PEDIATRICS ◽  
1995 ◽  
Vol 95 (5) ◽  
pp. 773-776
Author(s):  
John P. Kinsella ◽  
Jeffrey M. Schmidt ◽  
Jeff Griebel ◽  
Steven H. Abman
Keyword(s):  
Nitric Oxide ◽  
Respiratory Failure ◽  
Critically Ill ◽  
Tertiary Care ◽  
Inhaled Nitric Oxide ◽  
Hypoxemic Respiratory Failure ◽  
Emergency Medical ◽  
Medical Transport ◽  
Tertiary Care Centers ◽  
Inhaled No

Stabilization and transport of critically ill newborns and infants is a vital component of regionalized care. With the advent and proliferation of new therapies for the management of severe hypoxemic respiratory failure, emergency medical transport to tertiary care centers increasingly requires novel transport innovations. Inhaled nitric oxide (NO) therapy has been used in the management of severe persistent pulmonary hypertension of newborns (PPHN) and of hypoxemic respiratory failure in older pediatric patients.1-5 We report the use of inhaled NO therapy during transport in six patients with critical hypoxemia. This report describes a practical approach to stabilization and transport of critically ill newborns and infants using inhaled NO.

scholarly journals Inhaled Nitric Oxide Use in Pediatric Hypoxemic Respiratory Failure

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
John T. Berger ◽  
Aline B. Maddux ◽  
Ron W. Reeder ◽  
Russell Banks ◽  
Peter M. Mourani ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Respiratory Failure ◽  
Inhaled Nitric Oxide ◽  
Hypoxemic Respiratory Failure

scholarly journals Longitudinal follow-up in Preterm and Full Term Newborns Treated with Inhaled Nitric Oxide (iNO) for Severely Hypoxemic Respiratory Failure

1999 ◽  
Vol 45 (4, Part 2 of 2) ◽  
pp. 211A-211A
Author(s):  
Jean-Christophe Mercier ◽  
Peter Onody ◽  
Patrick Truffert ◽  
Josefa Llado-Paris ◽  
Anne Clerckx
Keyword(s):  
Nitric Oxide ◽  
Respiratory Failure ◽  
Full Term ◽  
Inhaled Nitric Oxide ◽  
Hypoxemic Respiratory Failure ◽  
Term Newborns

scholarly journals INHALED NITRIC OXIDE IN COVID-19-INDUCED HYPOXEMIC RESPIRATORY FAILURE

CHEST Journal ◽  
2021 ◽  
Vol 160 (4) ◽  
pp. A1125-A1126
Author(s):  
Siva Naga Yarrarapu ◽  
Abhishek Giri ◽  
Israr Baloch ◽  
Nirmaljot Kaur ◽  
Augustine Lee ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Respiratory Failure ◽  
Inhaled Nitric Oxide ◽  
Hypoxemic Respiratory Failure

Use and costs of inhaled nitric oxide and inhaled epoprostenol in adult critically ill patients: A quality improvement project

2019 ◽  
Vol 76 (18) ◽  
pp. 1413-1419 ◽  
Author(s):  
Stephanie L Davis ◽  
Jessica R Crow ◽  
John R Fan ◽  
Katie Mattare ◽  
Glenn Whitman ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Quality Improvement ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Academic Medical Center ◽  
Tertiary Care ◽  
Inhaled Nitric Oxide ◽  
Quality Improvement Project ◽  
Improvement Project ◽  
Number Of Patients

Abstract Purpose Inhaled epoprostenol and inhaled nitric oxide are pulmonary vasodilators commonly used in the management of acute respiratory distress syndrome and right ventricular failure; however, they have vastly different cost profiles. The purpose of the project was to transition from nitric oxide to epoprostenol as the inhaled pulmonary vasodilator (IPV) of choice in adult critically ill patients and evaluate the effect of the transition on associated usage and costs. Methods A single-center, prospective, before and after quality improvement project including adult patients receiving inhaled nitric oxide, inhaled epoprostenol, or both was conducted in 7 adult intensive care units, operating rooms, and postanesthesia care units of a tertiary care academic medical center. The total number of patients, hours of therapy, and costs for each agent were compared between stages of protocol implementation and annually. Results Seven hundred twenty-nine patients received inhaled nitric oxide, inhaled epoprostenol, or both during the study period. The monthly inhaled nitric oxide use in number of patients, hours, and cost decreased during all stages of the project (p < 0.01). The monthly inhaled epoprostenol use in number of patients, hours, and cost increased during all stages (p < 0.01). Overall, total IPV use increased during the study. However, despite this increase in usage, there was a 47% reduction in total IPV cost. Conclusion Implementation of a staged protocol to introduce and expand inhaled epoprostenol use in adult critically ill patients resulted in decreased use and cost of inhaled nitric oxide. The total cost of all IPV was decreased by 47% despite increased IPV use.

Sign in / Sign up

Export Citation Format

Share Document